December 2019 Private and confidential 1
Presentation Disclaimer The information contained in this document (the “Presentation”) has been prepared by SV Pharma Limited (“SVP”). SVP is a private limited company. This Presentation has not been verified and is subject to material updating, revision and verification and amendment without notice. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (as amended) (“FSMA”) and therefore it is being provided for information purposes only. Reliance on this Presentation for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested. While the information contained herein has been prepared in good faith, neither SVP nor any of its current or proposed directors, officers, agents, employees or advisers give, have given or have authority to give, any representations or warranties (express or implied) as to, or in relation to, the accuracy, reliability or completeness of the information in this Presentation, or any revision thereof, or of any other written or oral information made or to be made available to any interested party or its advisers (all such information being referred to as “Information”) and liability therefore is expressly disclaimed. Accordingly, neither SVP nor any of its current or proposed directors, officers, agents, employees or advisers take any responsibility for, or will accept any liability whether direct or Indirect, express or implied, contractual, tortious, statutory or otherwise, in respect of, the accuracy or completeness of the Information or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, howsoever arising, from the use of this Presentation. The views of the SVP’s management/directors and/or its partners/representatives set out in this Presentation could ultimately prove to be incorrect. No warranty, express or implied, is given by the presentation of these figures here and investors should place no reliance on SVP’s estimates cited in this Presentation. This Presentation may contain “forward-looking statements” that involve substantial risks and uncertainties, and actual outcome and developments may differ materially from those expressed or implied by these statements or a variety of factors. These forward-looking statements are statements regarding SVP’s intentions, beliefs or current expectations concerning, among other things, SVP’s performance, financial condition, prospects, growth, strategies and the industry in which SVP operates. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. These forward-looking statements speak only as of the date of this Presentation and SVP does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date of this Presentation. This Presentation should not be considered as the giving of investment advice by the SVP or any of its directors, officers, agents, employees or advisers. In particular, this Presentation does not constitute or form part of any offer or invitation to subscribe for or purchase any securities and neither this Presentation nor anything contained herein shall form the basis of any contract or commitment whatsoever. No reliance may be placed for any purpose whatsoever on the information or opinions contained in these slides or the Presentation or on the completeness, accuracy or fairness thereof. In particular, any estimates or projections or opinions contained herein necessarily involve significant elements of subjective judgment, analysis and assumptions and each recipient should satisfy itself in relation to such matters. Neither this Presentation nor any copy of it may be (a) taken or transmitted into Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or the United States of America (each a “Restricted Territory”), their territories or possessions; (b) distributed to any U.S. person (as defined in Regulation S under the United States Securities Act of 1933 (as amended)) or (c) distributed to any individual outside a Restricted Territory who is a resident thereof in any such case for the purpose of offer for sale or solicitation or invitation to buy or subscribe any securities or in the context where its distribution may be construed as such offer, solicitation or invitation, in any such case except in compliance with any applicable exemption. The distribution of this document in or to persons subject to other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of the laws of the relevant jurisdiction. This Presentation is being made available on the basis that recipients keep confidential any information contained herein, whether orally or in writing, in connection with SVP. This Presentation is confidential and must not be copied, reproduced, published, distributed, disclosed or passed to any other person at any time without the prior written consent of SVP. Prospective investors should not construe the contents of this Presentation as legal, tax, investment or other advice. All prospective investors should make their own enquiries and consult their own advisers as to legal, tax, investment, and related matters concerning an investment in SVP. By accepting a copy of this Presentation you agree to be bound by the foregoing provisions. 2
SV Pharma’s Vision Our goal is to build Europe’s most innovative cannabis extraction business and become the leading pharma grade cannabis company in Europe, setting the gold- standard in cultivation and extraction 3
Company Overview Extraction and German THC Trading Large Scale Pharma Refining Licence Operation Short term cash generative Providing a foothold in the Unlimited THC cultivation and business largest medical cannabis processing licence via JV with market in Europe leading pharma company SV Pharma has acquired ethanol extraction and SV Pharma holds a trading JV with Zada Pharmaceuticals refining equipment from a licence for THC in Germany Bosnia, GMP certified THC leading US manufacturer to which includes import / cultivation, extraction and install in German facility. export and distribution. processing facility Will produce high grade CBD Licence currently allows for SV Pharma holds 62% of JV with distillate/isolate for trading of 160kg of flower per Zada to contribute an initial €6 wholesale. year. mill towards land and buildings. Generating fast cash flow. Work underway to expand Construction scheduled to licence, increasing capacity, commence in Q2 2020. Extraction scheduled to for full commercialisation. commence in Q1 2020. 4 4
European Hemp / CBD- A large undeveloped emerging market Traditionally used for food & fibre, hemp is now being used to produce a variety of medicinal • and healthcare products – largely hemp derived cannabidiol In Europe, hemp is defined as cannabis containing less than 0.2% THC • The hemp flower can be used to • create crude oil, distillate and an isolate depending on the intended use Estimated current product demand • outstrips supply 5 to 1 Significant demand in Europe for • consistent high quality CBD Germany cultivated 2,147 hectares • of hemp in 2017, 43% more than 2016 and increasing year on year 5
The Opportunity Europe is estimated to produce close to 1/4 of the world’s hemp crop • European CBD market expected to boom - the market was estimated at $318 million in 2018 • and is expected to grow over 400 percent through 2023 (1) But while hemp production and demand have rapidly grown, high quality extraction and • processing has lagged SV Pharma is poised to become a leading provider of CBD distillate and isolate in Europe • With speed to market a priority we will capture this opportunity and become a top player in • the European extraction industry generating high returns on capital 6 (1) Brightfield Group - 26 March 2019
SV Pharma Extraction Overview SV Pharma is expecting delivery of its first 500 Gallon Industrial Performance Integrated Extraction and Recovery Solution on site in Germany in Q1 2020. Fully licensed operation to be located in Berlin, Germany with a focus on • scalability Ethanol extraction and recovery system represents the newest and most • innovative extraction technology in the marketplace First production planned for Q1 2020 – 3 month ramp up • Scalable operations: • 2 nd extraction unit planned to come online in Q4 2020 • Working with equipment suppliers to manufacture new solutions for • specific products Rigid Quality Assurance • Third-party testing at each stage (independent lab on site) • GMP certification to commence in 2020 • Key Stats • 360kg daily processing volume based on single shift • Producing 23 liters of CBD distillate per shift • 7
Recommend
More recommend
